Passing PMTA Acceptance & Filing Review: The Stage Most Applications Stumble
Answers: “PMTA acceptance and filing review requirements”
Before FDA ever reaches substantive scientific review, a PMTA must clear acceptance and filing review — administrative and threshold-completeness gates where many applications stall. Getting past this gate is the difference between your file being read and being returned.
What helps a file clear the gate
- Completeness across evidence elements — toxicology (ELCR), PK, and population impact (PHIA) all present, not just one.
- Reviewer-ready formatting to §1114.7, in all-English.
- Traceable sourcing — 14–21 citations so claims are auditable.
- Internal consistency — the same numbers and section references used everywhere.
No tool can guarantee a Marketing Granted Order. What rigorous, computed §1114.7 evidence does is materially raise your odds of clearing acceptance and filing review — the stage most applications stumble at — so your file advances to substantive review.
Pros vs. cons. Pro: front-loading complete, consistent, well-sourced evidence directly targets the most common early rejection reasons. Con: clearing acceptance/filing is a threshold, not approval — substantive review still weighs the science on its merits.
Who should NOT buy: applicants whose bottleneck is substantive scientific deficiency, not completeness — modeling completeness won't fix a weak underlying product.
FAQ
Does this guarantee my PMTA is accepted?
No. It raises the odds of clearing acceptance/filing by improving completeness and formatting; outcomes are FDA's decision.
Why do applications fail early?
Commonly incompleteness and formatting/consistency issues at acceptance and filing.
See your formula’s evidence today
Run ELCR, in-silico PK and PHIA in your browser — a §1114.7-ready report in hours.
Start free — no signup